Yves Cohen

ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada.

Bluewater Bio Ltd. is a holding company, which provides wastewater treatment services. Its technologies include HYBACS, FilterClear, Neo Tech, CFIC and GHG-Tox. The firm also provides operational and maintenance services. The company operates through its offices located in Kirkintilloch, Gauteng, Cape Town and Saudi Arabia. Bluewater Bio was founded by Daniel Ishag and Adrian Harris in 2007 and is headquartered in London, the United Kingdom.